|

Redirecting Immune, Lipid and Metabolic Drivers of Early Cardiovascular Disease: The RESET Cohort Study

RECRUITINGSponsored by National University Hospital, Singapore
Actively Recruiting
SponsorNational University Hospital, Singapore
Started2024-03-01
Est. completion2029-09-01
Eligibility
Age40 Years – 70 Years
View on ClinicalTrials.gov →

NCT06211868

Summary

Project RESET is a Singapore National Medical Research Council Large Collaborative Grant funded program that brings together a nationwide community of cardiovascular, metabolic, and digital health researchers, as well as clinicians across primary and tertiary care to study the immune, lipid and metabolic drivers of early cardiovascular disease. RESET incorporates a nested randomised controlled trials (RCT) to test the use of a combined digital wearable and AI-human symbiotic lifestyle intervention to halt or reverse the progression of early disease.

Eligibility

Age: 40 Years – 70 Years
Inclusion Criteria:

* 40-70 years old
* ASCVD (atherosclerotic cardiovascular disease) score of 5% and higher

Exclusion Criteria:

* Previous major cardiovascular disease (myocardial infarction, heart failure, ischemic stroke)
* Limited life expectancy
* Other ongoing unstable medical conditions
* Pregnant women

Conditions4

Cardiovascular DiseasesLiver DiseaseMetabolic SyndromeNon Alcoholic Fatty Liver Disease

Browse More Trials

Liver Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.